Rami Manochakian: FDA Oncology approves the combination of Encorafenib and Binimetinib for Patients with metastatic Non-Small cell Lung Cancer with a BRAF V600E mutation.

Rami Manochakian: FDA Oncology approves the combination of Encorafenib and Binimetinib for Patients with metastatic Non-Small cell Lung Cancer with a BRAF V600E mutation.

Rami Manochakian, Thoracic medical oncologist at Mayo Clinic, shared on Twitter:
“Hot off the press! FDA Oncology approves the combination of Encorafenib and Binimetinib for Patients with metastatic Non-Small cell Lung Cancer with a BRAF V600E mutation.
Approval is based on PHAROS trial (an open-label, multicenter, single-arm study) which showed:
  • ORR in treatment naive patients: 75%
    mDoR: Not estimable
  • ORR in previously treated patients: 46%
    mDoR: 16.7 months”
For the article click here.
Source: Rami Manochakian/Twitter

 

binimetinib cancer encorafenib FDA non small cell lung cancer OncoDaily Oncology PHAROS Rami Manochakian